Figure 2. Strong association between minimal residual disease status after two cycles of 3F8/GM-CSF immunotherapy (post-MRD) and event-free survival of the 170 patients (p < 0.001).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.